文献速递胸部肿瘤

体重指数影响二甲双胍对I期非小细胞肺癌肺叶切除术后生存的益处

Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC.
PubMed 文献 · J Thorac Oncol · 2019-08-06

结果显示仅在高BMI(>25 kg/m2)患者中,二甲双胍使用与总生存(HR=0.52;p=0.04)和疾病特异性生存(HR=0.21;p=0.04)改善相关,无复发生存无显著关联(HR=0.67;p=0.33)。另一205例晚期肿瘤队列的基因表达数据支持高BMI患者中二甲双胍使用与免疫检查点基因下调相关。

要点

  • 高BMI(>25 kg/m2)的I期NSCLC肺叶切除术后患者使用二甲双胍与总生存和疾病特异性生存改善相关。
  • 低BMI(≤25 kg/m2)患者中未观察到二甲双胍的生存获益。
  • 高BMI患者中二甲双胍使用与免疫检查点基因表达下调相关,低BMI患者中则上调。

核心结论

  • 二甲双胍使用可能仅在高BMI(>25 kg/m2)的I期非小细胞肺癌肺叶切除术后患者中与更好的总生存和疾病特异性生存相关。

研究设计与样本

  • 另设205例晚期肿瘤患者队列(其中35例使用二甲双胍)分析免疫检查点基因表达。

主要发现

  • 在高BMI患者中,二甲双胍使用与总生存相关(HR=0.52;p=0.04),与疾病特异性生存相关(HR=0.21;p=0.04),与无复发生存无显著关联(HR=0.67;p=0.33)。
  • 在205例晚期肿瘤患者队列中,二甲双胍使用者免疫检查点基因(PD-1、CTLA-4、BTLA、CD27、LAG3、ICOS)表达下调仅见于高BMI患者,低BMI患者中这些基因表达上调。

临床怎么用

  • 对于高BMI(>25 kg/m2)的I期NSCLC肺叶切除术后患者,二甲双胍使用可能与生存改善相关,但需进一步研究验证。

局限性

  • 原文未报告具体局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Metformin, a common medication used in the treatment of diabetes mellitus is known to have anticancer effects. We hypothesized that the salutary effect of metformin on the survival of patients with stage I NSCLC is influenced by body mass index (BMI). METHODS: Patients undergoing lobectomy for stage I NSCLC without neoadjuvant therapy were included. Univariate and multivariate survival analyses to examine the association between metformin use and overall survival (OS), disease-specific survival (DSS), and recurrence-free survival were performed, stratified by BMI (>25 kg/m2 and ≤25 kg/m2). Expression of immune checkpoints in patients on metformin and not was performed in a separate cohort of 205 patients with advanced disease. RESULTS: Four hundred thirty-four stage I patients (including 74 metformin users) were deemed eligible for analysis. Univariate and multivariate analysis revealed an association between metformin use and OS (hazard ratio [HR] = 0.52; p = 0.04) as well as DSS (HR = 0.21; p = 0.04) but not recurrence-free survival (HR = 0.67; p = 0.33) in high-BMI patients only. In a separate cohort of 205 patients with tumors of all stages (including 35 metformin users), downregulation of immune checkpoint gene expression (programmed cell death 1, cytotoxic T-lymphocyte associated protein 4, B and T lymphocyte associated, CD27 molecule, lymphocyte activating 3, and inducible T cell costimulator) in metformin users was seen only in high-BMI patients, with upregulation of these genes seen in low-BMI patients with metformin use. CONCLUSIONS: Metformin use may be associated with better OS and DSS only in high-BMI patients. This hypothesis is supported by gene expression data of immune checkpoint genes in metformin users using a separate cohort of advanced-stage tumors. Further studies examining the interaction of BMI with metformin in NSCLC are worthwhile.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yendamuri S, Barbi J, Pabla S, et al. Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC. J Thorac Oncol. 2019. PMID: 31398539. doi:10.1016/j.jtho.2019.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。